Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc.

Agios is focused on developing therapies for rare hemolytic anemias. Our first rare disease therapy was approved by the FDA for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. The lead product candidate in our clinical portfolio, mitapivat, is being evaluated in late-stage clinical trials for thalassemia and sickle cell disease. We are also developing AG-946, a novel PK activator, for the potential treatment of hemolytic anemias and other indications. Our research engine is advancing multiple novel, investigational therapies in preclinical development.

Yes